Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aslan Pharmaceuticals Ltd ADR (ASLN)
NASDAQ:ASLN
Aslan Pharmaceuticals (ASLN) Stock Price & Analysis
405 Followers
ASLN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.39 - $4.69
Previous Close$0.46
Volume158.25K
Average Volume (3M)1.26M
Market Cap
$7.97M
Enterprise Value$13.62M
Total Cash (Recent Filing)$21.25M
Total Debt (Recent Filing)$26.83M
Price to Earnings (P/E)-0.2
Beta1.82
Next Earnings
Aug 13, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding23,482,988
10 Day Avg. Volume1,600,121
30 Day Avg. Volume1,257,862
Standard Deviation0.36
R-Squared0.04
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-0.81
Price to Sales (P/S)0.63
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.13
Enterprise Value/Ebitda-0.62
Forecast
1Y Price Target
$9.50Price Target Upside1997.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Aslan Pharmaceuticals News
PremiumCompany Announcements
Aslan Pharmaceuticals’ Eblasakimab Shows Promise
PremiumCompany Announcements
ASLAN Pharma Faces Nasdaq Compliance ChallengeBulls Say, Bears Say
Bulls Say
Clinical Study ResultsASLAN Pharmaceuticals announced positive interim data from the TREK-DX study of eblasakimab in dupilumab-experienced atopic dermatitis patients, showing a rapid onset of action and significant improvements in severity scores.
Market OpportunityWith over 60% of patients treated with dupilumab failing to achieve optimal results, eblasakimab presents a significant market opportunity as a potential treatment for atopic dermatitis.
Safety And EfficacyEblasakimab demonstrates a strong safety profile with no new safety signals identified, coupled with robust efficacy outcomes, indicating its potential as a long-term treatment option for atopic dermatitis.
Bears Say
Capital RequirementsDue to the company’s near-term capital requirement and current share price, the discount rate was increased from 15% to 18%.
Financial PerformanceNet loss totaled $44.2M in 2023.
Future ExpectationsClinical catalysts expected in 2024.
---
Ownership Overview
0.00%
Insiders
0.04% Mutual Funds
0.10% Other Institutional Investors
99.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ASLN FAQ
What was Aslan Pharmaceuticals Ltd ADR’s price range in the past 12 months?
Aslan Pharmaceuticals Ltd ADR lowest stock price was $0.39 and its highest was $4.69 in the past 12 months.
What is Aslan Pharmaceuticals Ltd ADR’s market cap?
Currently, no data Available
When is Aslan Pharmaceuticals Ltd ADR’s upcoming earnings report date?
Aslan Pharmaceuticals Ltd ADR’s upcoming earnings report date is Aug 13, 2024 which is in 103 days.
How were Aslan Pharmaceuticals Ltd ADR’s earnings last quarter?
Currently, no data Available
Is Aslan Pharmaceuticals Ltd ADR overvalued?
According to Wall Street analysts Aslan Pharmaceuticals Ltd ADR’s price is currently Undervalued.
Does Aslan Pharmaceuticals Ltd ADR pay dividends?
Aslan Pharmaceuticals Ltd ADR does not currently pay dividends.
What is Aslan Pharmaceuticals Ltd ADR’s EPS estimate?
Aslan Pharmaceuticals Ltd ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aslan Pharmaceuticals Ltd ADR have?
Aslan Pharmaceuticals Ltd ADR has 22,626,814 shares outstanding.
What happened to Aslan Pharmaceuticals Ltd ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aslan Pharmaceuticals Ltd ADR?
Among the largest hedge funds holding Aslan Pharmaceuticals Ltd ADR’s share is Platinum Investment Management. It holds Aslan Pharmaceuticals Ltd ADR’s shares valued at N/A.
---
Aslan Pharmaceuticals Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.50 (1997.13% Upside)
$9.50 (1997.13% Upside)
Hedge Fund Trend
Decreased
By 29.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-59.75%
Trailing 12-Months
Company Description
Aslan Pharmaceuticals Ltd ADR
Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002. The firm's portfolio focuses on validated growth pathways applied to new patient segments, novel immune checkpoints, and novel cancer metabolic pathways. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.
---
ASLN Stock 12 Months Forecast
Average Price Target
$9.50
▲(1997.13% Upside)
Technical Analysis
Best Analysts Covering ASLN
1 Year
1 Year Success Rate
4/22 ratings generated profit
1 Year Average Return
-43.25%
reiterated a buy rating 10 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -43.25% per trade.
---